

## PHARMACIST ASSESSMENT – ACUTE UNCOMPLICATED CYSTITIS

Patient Information   Informed consent obtained	🗆 PharmaNet Check 🛛 🗆 Patient Eligible			
Name:	PHN:	DOB:	(Age < 16→ Refer)	
Address: (Long term care → Refer)	□Allergies:		□ Female →Continue □ Male →Refer □ Other →Assess	
Telephone:	□Pregnant→Refer □ Breastfeeding/Chestfeeding (if infant <1 month→Refer)			
Medical History				
<b>Previous episode(s) of UTI diagnosed?</b> $\Box$ Yes $\rightarrow$ Continue $\Box$ No $\rightarrow$ Refer				
Previous episode of UTI within last 1 month? $\Box$ Yes $\rightarrow$ Refer $\Box$ No $\rightarrow$ Continue				
<ul> <li>≥2 uncomplicated UTIs in 6 months or ≥3 uncomplicated UTIs in 12 months AND:</li> <li>a) patient takes a medication associated with increased risk of UTI (e.g. SGLT2 Inhibitor) OR</li> <li>b) patient is interested in prophylactic therapy (e.g. postcoital antibiotics, ongoing antibiotic treatment)</li> <li>□Yes → Refer; may still prescribe for this episode</li> <li>□ No → Continue</li> </ul>				
<ul> <li>Abnormal urinary tract function or structure (indwelling catheter, neurogenic bladder, renal stones, renal dysfunction, etc.) → Refer</li> <li>Renal impairment (CrCl = ): If &lt;60 mL/min → Refer</li> <li>Spinal cord injury → Refer</li> <li>Immunocompromised due to disease, or poorly controlled diabetes → Refer</li> <li>History of interstitial cystitis → Refer</li> <li>Medical History:</li> </ul>				
Drug History/Drug Allergies				
<ul> <li>□ Immunocompromised due to medication → Refer</li> <li>□ Medication which can cause cystitis symptoms (e.g. cyclophosphamide, allopurinol, danazol, tiaprofenic acid) → Refer for further investigation, consideration of alternatives or discontinuation</li> <li>Drug History:</li> </ul>				
Review of Symptoms				
Are any red flag symptows present?         □ Fever       □ Nausea or vomiting         □ Chills       □ Vaginal discharge or pruritus         □ Flank or back pain       □ Dyspareunia (painful intercourse)         □ Significant malaise       □ Significant hematuria         □ No → Continue       □ Yes → Consider alternate diagnosis / refer         Are symptoms typical curve uncomplicated cystitis?         □ Dysuria       □ Frequency         □ Urgency       □ Suprapubic pain or mild hematuria         □ Yes → Continue       □ No → Refer for further investigation				

Symptom Review Summary			
<ul> <li>Appropriate to proceed with minor ailment treatment</li> <li>Advised to see another health care provider as out of scope</li> </ul>			
<b>Treatment</b> *if breastfeeding/chestfeeding – see "treatment" section in guideline*			
Prior treatment for UTI: Medication: Tolerance:	Date of last UTI: Effect:		
<ul> <li>First Line:</li> <li>Nitrofurantoin monohydrate/macrocrystals (BID product) 100 mg PO TWICE daily x 5 days</li> <li>Or</li> <li>Nitrofurantoin macrocrystals 50–100 mg PO FOUR times daily x 5 days</li> </ul>			
Second Line: Sulfamethoxazole-trimethoprim 800 mg / 160 mg PO Or Trimethoprim 100 mg PO TWICE daily x 3 days Or Trimethoprim 200 mg PO ONCE DAILY x 3 days	TWICE daily x 3 days (Avoid if used in the previous 3 months)		
Third Line: (Reserve for resistant infections or for patients unable to take first and second line) <ul> <li>Fosfomycin 3 g dissolved in ½ cup of cold water PO x 1 dose</li> </ul>			
□ Other:			
Prescription Issued for Minor Ailment			
Rationale for prescribing: Rx:			
Quantity (enough for one course of treatment only):			
Directions:			
*if breastfeeding/chestfeeding – see "treatment" section in guideline*			
Other Recommendations (e.g. OTC, self-care, referral to other health care provider)			
<b>Counselling</b> Aay have prescription filled at pharmacy of choice	PAR will be communicated to primary care provider as part of collaborative practice		
□Common side effects of medication □Non-pharmacologic e.g. adequate fluid intake □Expect symptom improvement within 48-72 hours			
Follow up scheduled in 3 days:			
In pharmacy     DTelepho	ne		

<ul> <li>□ Assess for significant improvement of all symptoms</li> <li>□ Determine if side effects are occurring (esp. severe diarrhea or rash)</li> <li>□ If worsening or not improving → Refer</li> <li>□ If improving → Encourage continued use until the end of therapy if greater than 3 days</li> </ul>			
Prescribing pharmacist			
Name:	Pharmacist License Number:		
Pharmacy:	Pharmacy Address:		
Signature: Rph	Date:		
Telephone:	Fax:		
Primary Care Provider Notified (Date):	Method of Notification:		
Primary Care Provider:	Fax:		

No part of this work may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the copyright holder. For copyright permission requests, please

contact <u>druginfo@usask.ca</u>.

## То This document is to inform you I met with your patient below who presented with an acute uncomplicated cystitis. The patient has had this issue previously diagnosed. After an assessment, a prescription was issued for The prescription details and rationale for my decision are documented below. This is for your information to keep your records for this patient up to date. **Patient Demographics:** Name: PHN: DOB: Address: Telephone: □ Breastfeeding/Chestfeeding **Prescription Issued on** MEDICATION: DIRECTIONS: QUANTITY: Rationale for prescription / relevant patient information: I will follow-up with the patient on and discuss these items: □ Assess for significant improvement of all symptoms Determine if side effects are occurring (esp. severe diarrhea or rash) $\Box$ If worsening or not improving $\rightarrow$ Refer $\Box$ If improving $\rightarrow$ Encourage continued use until the end of therapy if greater than 3 days **Prescribing Pharmacist:** Pharmacist License Number: Name: Pharmacy: Pharmacy Address: Signature: Date: Telephone: Fax: Primary Care Provider Notified (Date): Method of Notification:

No part of this work may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the copyright holder. For copyright permission requests, please contact druginfo@usask.ca.

Fax:

Name: